To test this, the researchers conducted a retrospective chart review of patients that underwent RFA for primary treatment for SRMs at their center between November 2007 and October 2017. The urologic team analyzed perioperative and baseline data including patient age, sex, pathology, maximum tumor size, PADUA score, and RENAL Nephrometry score (shown below). If patients had family history and oncocytoma was confirmed on biopsy, the patient would be excluded from the study. It is worth noting that repeat RFA at the ipsilateral kidney for recurrence or incomplete ablation was not considered a new procedure. Primary carriable measured was the time from initial ablation to recurrence. Incomplete ablations were defined as evidence of residual tumor at the original ablation site.
Dr. Kapoor concluded by admitting the study was only a retrospective, single-center trial with a relatively small sample size and low event rate. In order for this to be more convincing study, a prospective, randomized controlled, multicenter trial must be conducted. However, Dr. Kapoor concluded that the risk of recurrence was very low in patients treated at his center with a large margin for success and no long-term recurrence past 30 months.
Presented by: Anil Kapoor, MD, Department of Surgery, Division of Urology, McMaster University, Hamilton
Co-Authors: Cameron Lam1, Michael Nixon2, Nathan Wong1, Edward Matsumoto1
1Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada; 2Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
Written by: Zachary Valley, MD, Twitter: @ZacharyAValley, Department of Urology, University of California-Irvine at the 73rd Canadian Urological Association Annual Meeting - June 23 - 26, 2018 - Halifax, Nova Scotia